Queen’s Partnerships and Innovation is pleased to report the issuance of U.S. Patent No. 11,364,220 entitled, "Compounds and Methods for Inhibiting CYP26 Enzymes," on June 21, 2022 to Johnathan Board, Donald Cameron, Ashishkumar Maheta, Martin Petkovich, Toni Rantanen, and Suneel Singh. The patent relates to compounds that are inhibitors of retinoic add inducible P450 (CYP26) enzymes, and are useful for treating diseases that are responsive to retinoids.
U.S. Patent No. 11,364,220 (PDF, 1.7 MB)US11364220_Cameron.pdf